Business Context and Reporting Period
Company: ReWalk Robotics Ltd. (Note: Input metadata referenced "Lifeward Ltd.", but the filing text identifies the registrant as ReWalk Robotics Ltd.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2019 (Events occurred June 5-6, 2019)
Context: The Company entered into warrant exercise agreements with institutional investors to exercise public warrants issued in a November 2018 follow-on offering.
Key Financial Metrics
- Gross Proceeds: Approximately $11 million from the exercise of 1,464,665 ordinary shares.
- Exercise Price: $7.50 per share.
- Transaction Costs: Placement agent fees and expenses of approximately $1 million.
- Placement Agent Fees: 7.5% cash placement fee, 1.0% management fee, $30,000 expense allowance, and up to $50,000 legal reimbursement.
- Placement Agent Warrants: Warrants issued for 6.0% of the aggregate shares issued, exercisable at $9.375 per share (125% of exercise price).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or margins as this is a transaction report, not a periodic financial statement.
Material Changes
This filing reports a specific capital event rather than a period-over-period financial comparison. The material change is the increase in cash proceeds and the issuance of new equity instruments:
- Equity Issuance: 1,464,665 ordinary shares issued upon warrant exercise.
- New Warrants Issued: 1,464,665 Private Placement Warrants issued to holders (5-year term, $7.50 exercise price) and Wainwright Warrants issued to the placement agent.
- Liquidity Impact: Immediate infusion of approximately $11 million in gross cash proceeds.
Guidance, Outlook, and Risks
Use of Proceeds: Management intends to use the funds for:
- Sales, marketing, and reimbursement expenses for the ReStore device and ReWalk Personal device.
- Research and development for lightweight exo-suit technology targeting lower limb disabilities (e.g., stroke).
Risks and Contingencies:
- Ownership Blockers: Holders are restricted from exercising Private Placement Warrants if it results in ownership exceeding 4.99% (or 9.99% with notice).
- Representations: The filing notes that representations in the exercise agreements are for risk allocation between parties and may not reflect current facts or shareholder materiality standards.
Investor Verification Checklist
- Verify the net cash proceeds after deducting the ~$1 million in fees and expenses.
- Confirm the dilution impact of the 1,464,665 new shares and the associated Private Placement Warrants.
- Review the specific terms of the Private Placement Warrants (Exhibit 4.1) regarding anti-dilution adjustments and ownership caps.
- Assess the timeline for the deployment of funds into R&D for the exo-suit technology versus commercialization of existing devices.